Magazine Article | July 1, 2021

Against All Odds: Advancing From R&D To Phase 3

Source: Life Science Leader

By Sanjeev Luther

To pave a path in a field that is bound to be riddled with disappointments, uncertainties, and sometimes even utter failure, would deter most people from creating a career in biopharma. Harrowing statistics illustrate the hardships in successfully bringing a drug to market. In fact, over 90% of compounds never even enter Phase 1 clinical trials — a number that has not changed in decades. Advancing a pharmaceutical company is an uphill battle, with many challenges along the way from data analysis to FDA regulations to trial operations and beyond.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader